Main roads to melanoma

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages

  Palmieri, Giuseppe ^a   Capone, Mariaelena ^b   Ascierto, Maria L ^b   Gentilcore, Giusy ^b   Stroncek, David F ^c   Casula, Milena ^a   Sini, Maria C ^a   Palla, Marco ^b   Mozzillo, Nicola ^b   Ascierto, Paolo A ^b  

^a CNR   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; BRAF PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; ISOENZYME; MITF PROTEIN, HUMAN; NITRIC OXIDE SYNTHASE;

APOPTOSIS; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CELL CYCLE ARREST; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; DNA METHYLATION; DOWN REGULATION; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; KERATINOCYTE; MELANOCYTE; MELANOMA; MOLECULAR DYNAMICS; MUTAGENESIS; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; SUN EXPOSURE; UPREGULATION; ANIMAL; CELL TRANSFORMATION; DISEASE COURSE; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN TUMOR;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; HUMANS; ISOENZYMES; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; NEOPLASM METASTASIS; NITRIC OXIDE SYNTHASE; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 71149083533     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-86     Document Type: Review

References (217)

1. Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006, 355:51-65.
2. Wolchok JD, Saenger YM. Current topics in melanoma. Curr Opin Oncol 2007, 19:116-20.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho J, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-54.
4. The Melanoma Molecular Map Project at. , http://www.mmmp.org/MMMP
5. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-47.
6. Mooi WJ, Peeper DS. Oncogene-induced cell senescence--halting on the road to cancer. New Engl J Med 2006, 355:1037-46.
7. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre' M, Nuciforo PG, Bensimon A, Maestro R, Pelicci PG, d'Adda di Fagagna F. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
8. Hong SK, Pusapati RV, Powers JT, Johnson DG. Oncogenes and the DNA damage response - Myc and E2F1 engage the ATM signaling pathway to activate p53 and induce apoptosis. Cell Cycle 2006, 5:801-803.
9. Di Micco R, Cicalese A, Fumagalli M, Dobreva M, Verrecchia A, Pelicci PG, di Fagagna F. DNA damage response activation in mouse embryonic fibroblasts undergoing replicative senescence and following spontaneous immortalization. Cell Cycle 2008, 7:3601-3606.
10. Bennett DC. Familial melanoma genes, melanocyte immortalization and melanoma initiation. Melanocytes to Melanoma: The Progression to Malignancy 2006, 183-96. New Jersey: Humana Press, Hearing VJ, Leong SPL.
11. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. The Lancet 2005, 365:687-701.
12. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006, 12:2301s-7s.
13. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The Ink4a tumor suppressor gene product, 19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998, 92:713-23.
14. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-51.
15. Bowen AR, Hanks AN, Allen SM, Alexander A, Diedrich MJ, Grossman D. Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol 2003, 120:48-55.
16. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005, 41:45-60.
17. Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. New Engl J Med 1999, 340:1341-8.
18. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 2003, 22:3099-112.
19. Eide MJ, Weinstock MA. Association of UV index, latitude, and melanoma incidence in non-White populations--US surveillance, epidemiology, and end results (SEER) program, 1992 to 2001. Arch Dermatol 2005, 141:477-481.
20. De Fabo EC, Noonan FP, Fears T, Merlino G. Ultraviolet B but not ultraviolet A radiation initiates melanoma. Cancer Res 2004, 64:6372-6.
21. Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW, Bart RS. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001, 44:837-46.
22. Moan J, Dahlback A, Setlow RB. Epidemiological support for an hypothesis for melanoma induction indicating a role for UVA radiation. Photochem Photobiol 1999, 70:243-247.
23. Oliveria S, Dusza S, Berwick M. Issues in the epidemiology of melanoma. Expert Rev Anticancer Ther 2001, 1:453-9.
24. Garland C, Garland F, Gorham E. Epidemiologic evidence for different roles of ultraviolet A and B radiation in melanoma mortality rates. Ann Epidemiol 2003, 13:395-404.
25. Takata M, Saida T. Genetic alteration in melanocytic tumors. J Dermat Science 2006, 43:1-10.
26. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001, 117:294-300.
27. Beaumont KA, Shekar SN, Newton RA, James MR, Stow JL, Duffy DL, Sturm RA. Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. Hum Mol Genet 2007, 16:2249-2260.
28. Kanetsky PA, Rebbeck TR, Hummer AJ, Panossian S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Culver HA, Zanetti R, Gallagher RP, Dwyer T, Busam K, From L, Mujumdar U, Wilcox H, Begg CB, Berwick M. Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res 2006, 66:9330-9337.
29. Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, Fargnoli MC. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer 2008, 122:2753-2760.
30. Box NF, Duffy DL, Irving RE, Russell A, Chen W, Griffyths LR, Parsons PG, Green AC, Sturm RA. Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. J Invest Dermatol 2001, 116:224-229.
31. Giehl K. Oncogenic Ras in tumor progression and metastasis. Biol Chem 2005, 386(3):193-205.
32. Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 2004, 14(2):105-14.
33. Pritchard CA, Samuels ML, Bosch E, McMahon M. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol 1995, 15:6430-42. 230894, 7565795.
34. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005, 23(27):6771-90.
35. Emuss V, Garnett M, Mason C, Marais R. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 2005, 65:9719-26.
36. Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger W, Windpassinger C, Schimek MG, Hoefler G, Troppmair J, Sill H. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res 2006, 66:3401-8.
37. Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Min WS, Kim SH, Lee JY, Yoo NJ, Lee SH. Mutational analysis of the ARAF gene in human cancers. APMIS 2005, 113:54-7.
38. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in papillary thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signalling pathway in papillary carcinoma. Cancer Res 2003, 63(7):1454-7.
39. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and Ras mutations in human lung cancer and melanoma. Cancer Res 2002, 62(23):6997-7000.
40. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C. Mutation of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52(5):706-12. 1773624, 12692057.
41. Palmieri G, Casula M, Sini MC, Ascierto PA, Cossu A. Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med 2007, 11:1052-1068.
42. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. Cancer Genome Project. Mechanism of activation of tha Ras-Erk signaling pathaway by oncogenic mutation on BRAF. Cell 2004, 116:855-867.
43. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, Denat L, Larue L, Goding CR. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005, 433:764-9.
44. Casula M, Colombino M, Satta MP, Cossu A, Ascierto PA, Bianchi-Scarrà G, Castiglia D, Budroni M, Rozzo C, Manca A, Lissia A, Carboni A, Petretto E, Satriano SM, Botti G, Mantelli M, Ghiorzo P, Stratton MR, Tanda F, Palmieri G, . Italian Melanoma Intergroup Study Braf gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup study. J Clin Oncol 2004, 22:286-92.
45. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS. High frequency of BRAF mutations in nevi. Nat Genet 2003, 33(1):19-20.
46. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003, 63(14):3883-5.
47. Greene VR, Johnson MM, Grimm EA, Ellerhorst JA. Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol 2009, 129:1483-1488. 2741006, 19037234.
48. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Berghmans S, Mayhall EA, Traver D, Fletcher CD, Aster JC, Granter SR, Look AT, Lee C, Fisher DE, Zon LI. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 2005, 15:249-54.
49. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
50. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374. 2266096, 18267069.
51. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. BRAF(E600) in benign and malignant human tumours. Oncogene 2008, 27:877-895.
52. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009, 15:294-303.
53. Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, Calista D, Kanetsky PA, Pinkel D, Bastian BC. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006, 313:521-2.
54. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A. Mutually exclusive N-RasQ61R and BRAF V600E mutations at the single-cell level in the same human melanoma. Oncogene 2006, 25:3357-64.
55. Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U. N-RAS mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 1998, 111:757-761.
56. El Shabrawi Y, Radner H, Muellner K, Langmann G, Hoefler G. The role of UV-radiation in the development of conjunctival malignant melanoma. Acta Ophthalmol Scand 1999, 77:31-32.
57. Ashida A, Takata M, Murata H, Kido K, Saida T. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 2009, 124:862-868.
58. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008, 14:6821-6828.
59. Stone S, Ping J, Dayananth P, Tavtigian SV, Katcher H, Parry D, Gordon P, Kamb A. Complex Structure and Regulation of the P16 (MTS1) Locus. Cancer Research 1995, 55:2988-2994.
60. Pho L, Grossman D, Laechman SA. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Current Opinion in Oncology 2006, 18:173-9.
61. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995, 83:993-1000.
62. Pacifico A, Leone G. Role of p53 and CKN2A inactivation in human squamous cell carcinomas. J Biomed Biotechnol 2007, 2007(3):43418. 1874671, 17541467.
63. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. MDM2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000, 275(12):8945-51.
64. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 1998, 17:5001-5014. 1170828, 9724636.
65. Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG. Low Prevalence of Germline CDKN2A and CDK4 Mutations in Patients With Early-Onset Melanoma. Arch Dermatol 2000, 136:1118-1122.
66. Piepkorn M. Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 2000, 42:705-722.
67. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
68. Box NF, Terzian T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res 2008, 21:525-533.
69. Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA. Association of MC1R Variants and Risk of Melanoma in Melanoma-Prone Families with CDKN2A Mutations. Cancer Epidemiol Biomarkers Prev 2005, 14(9).
70. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA, . Melanoma Genetics Consortium Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002, 94(12):894-903.
71. Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avri MF, Demenais F. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. Journal of the National Cancer Institute 2004, 96:785-95.
72. Puig S, Malvehy J, Badenas C, Ruiz A, Jimenez D, Cuellar F, Azon A, Gonzàlez U, Castel T, Campoy A, Herrero J, Martí R, Brunet-Vidal J, Milà M. Role of the CDKN2A Locus in patients with multiple primary melanomas. J Clin Oncol 2005, 23:3043-3051.
73. Eliason MJ, Hansen CB, Hart M, Porter-Gill P, Chen W, Sturm RA, Bowen G, Florell SR, Harris RM, Cannon-Albright LA, Swinyer L, Leachman SA. Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation. Arch Dermatol 2007, 143(11):1409-12.
74. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
75. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumour suppressor PTEN. Science 1998, 280:1614-1617.
76. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in PTEN +/- mice. Science 1999, 285:2122-2125.
77. Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonks N, Parsons R. The PTEN/MMAC1 tumour suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 1998, 58:5667-5672.
78. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Rulnd J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumour suppressor PTEN. Cell 1998, 95:29-39.
79. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Dev 1999, 13:2905-2927.
80. Brazil DP, Park J, Hemmings BA. PKB binding proteins: getting in on the Akt. Cell 2002, 111:293-303.
81. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signalling 2002, 14:381-95.
82. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, Kadowaki T, Hay N. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001, 15:2203-8. 312770, 11544177.
83. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB). Science 2001, 292:1728-31.
84. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 2001, 61:7318-24.
85. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive Activation Akt/Protein kinase B in Melanoma Leads to Up-Regulation of Nuclear factor-kB and Tumor Progression. Cancer Res 2002, 62:7335-7342.
86. Stokoe D. Pten. Curr Biol 2001, 11(13):R502.
87. Dahia PL. PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 2000, 7:115-129.
88. Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 1999, 253:210-229.
89. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004, 15:177-182.
90. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathwayin human cancer. Nat Rev Cancer 2002, 2:489-501.
91. Staal SP. Molecular cloning of the Akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natal Acad Sci 1987, 84:5034-7.
92. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR. Molecular alterations of the Akt2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995, 64:280-5.
93. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004, 64:7002-10.
94. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304(5670):554.
95. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7:561-73.
96. Omholt K, Krockel D, Ringborg U, Hansson J. Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res 2006, 16:197-200.
97. Curtin JA, Stark MS, Pinkel D, Hayward NK, Bastian BC. PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol 2006, 126:1660-3.
98. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
99. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005, 24:7435-7442.
100. Stiles B, Groszer M, Wang S, Jiao J, Wu H. PTENless means more. Dev Biol 2004, 273:175-184.
101. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
102. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321.
103. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci 2001, 98:11598-11603. 58775, 11504915.
104. Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 2002, 21:1299-1303.
105. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, Maya R, Moas M, Seger R, Taya Y, Ben-Ze'ev A. Regulation of p53: intricate loops and delicate balances. Biochem Pharmacol 2002, 64:865-871.
106. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
107. Romashkova JA, Makarov SS. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401:86-90.
108. Wan YS, Wang ZQ, Shao Y, Voorhees JJ, Fisher GJ. Ultraviolet irradiation activates PI 3-kinase/AKT survival pathway via EGF receptors in human skin in vivo. Int J Oncol 2001, 18:461-6.
109. Waldmann V, Wacker J, Deichmann M. Mutations of the activation-associated phosphorylation sites at codons 308 and 473 of protein kinase B are absent in human melanoma. Arch Dermatol Res 2001, 293:368-72.
110. Waldmann V, Wacker J, Deichmann M. Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma. Melanoma Res 2002, 12:45-50.
111. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008, 99:1265-1268. 2570525, 18813315.
112. Krasilnikov M, Adler V, Fuchs SY, Dong Z, Haimovitz-Friedman A, Herlyn M, Ronai Z. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog 1999, 24:64-9.
113. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001, 264:29-41.
114. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998, 273:13375-13378.
115. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 2000, 1470(1):M21-35.
116. Bonneau D, Longy M. Mutations of the human PTEN gene. Hum Mutat 2000, 16(2):109-22.
117. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem 2001, 70:247-279.
118. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Nat Cancer Inst 1999, 91:1922-1932.
119. Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998, 16(26):3397-402.
120. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-63.
121. Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H, Marsh DJ, Ritz J, Freedman A, Stiles C, Eng C. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 1999, 8:185-93.
122. Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA, Das S. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001, 91(1):22-6.
123. Fuse N, Yasumoto K, Takeda K, Amae S, Yoshizawa M, Udono T, Takahashi K, Tamai M, Tomita Y, Tachibana M, Shibahara S. Molecular cloning of cDNA encoding a novel microphthalmia-associated transcription factor isoform with a distinct amino-terminus. J Biochem 1999, 126:1043-1051.
124. Hodgkinson CA, Moore KJ, Nakayama A, Steingrímsson E, Copeland NG, Jenkins NA, Arnheiter H. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 1993, 74:395-404.
125. Hughes AE, Newton VE, Liu XZ, Read AP. A gene for Waardenburg syndrome type 2 maps close to the human homologue of the microphthalmia gene at chromosome 3p12-p14.1. Nat Genet 1994, 7:509-512.
126. Bentley NJ, Eisen T, Goding CR. Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol Cell Biol 1994, 14:7996-8006. 359338, 7969139.
127. Hemesath TJ, Steingrímsson E, McGill G, Hansen MJ, Vaught J, Hodgkinson CA, Arnheiter H, Copeland NG, Jenkins NA, Fisher DE. Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 1994, 8:2770-2780.
128. Yasumoto K, Yokoyama K, Shibata K, Tomita Y, Shibahara S. Micropthalmia-associated transcription factor as a regulator for melanocytespecific transcription of the human tyrosinase gene. Mol Cell Biol 1994, 14:8058-8070. 359344, 7969144.
129. Yasumoto K, Yokoyama K, Takahashi K, Tomita Y, Shibahara S. Functional analysis of microphthalmia-associated transcription factor in pigment cell-specific transcription of the human tyrosinase family genes. J Biol Chem 1997, 272:503-509.
130. Steingrímsson E, Copeland NG, Jenkins NA. Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet 2004, 38:365-411.
131. Selzer E, Wacheck V, Lucas T, Heere-Ress E, Wu M, Weilbaecher KN, Schlegel W, Valent P, Wrba F, Pehamberger H, Fisher D, Jansen B. The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res 2002, 62:2098-2103.
132. Opdecamp K, Nakayama A, Nguyen MT, Hodgkinson CA, Pavan WJ, Arnheiter H. Melanocyte development in vivo and in neural crest cell cultures: crucial dependence on the MITF basic-helix-loop-helix-zipper transcription factor. Development 1997, 124:2377-2386.
133. Wellbrock C, Marais R. Elevated expression of MITF counteracts B-RAF stimulated melanocyte and melanoma cell proliferation. J Cell Biol 2005, 170:703-708. 2171350, 16129781.
134. Hoek KS, Eichhoff OM, Schlegel NC, Döbbeling U, Kobert N, Schaerer L, Hemmi S, Dummer R. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008, 68:650-656.
135. Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D, Das Gupta TK. Microphthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 2000, 60:5012-5016.
136. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Hersey P. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 2007, 20:416-426.
137. King R, Googe PB, Weilbaecher KN, Mihm MC, Fisher DE. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for melanoma diagnosis. Am J Path 1999, 155:731-738. 1866880, 10487831.
138. Miettinen M, Fernandez M, Franssila K, Gatalica Z, Lasota J, Sarlomo-Rikala M. Micropthamia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol 2001, 25:205-211.
139. Chang KL, Folpe AL. Diagnostic utility of microphthalmia transcription factor in malignant melanoma and other tumors. Adv Anat Pathol 2001, 8:273-275.
140. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006, 12:406-14.
141. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-22.
142. Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 2006, 6:593-602.
143. Loercher AE, Tank EM, Delston RB, Harbour JW. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 2005, 168:35-40. 2171666, 15623583.
144. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, Fisher DE. Critical role of CDK2 for melanoma growth linked to its melanocytespecific transcriptional regulation by MITF. Cancer Cell 2004, 6:565-76.
145. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin YL, Ramaswamy S, Avery W, Ding HF, Jordan SA, Jackson IJ, Korsmeyer SJ, Golub TR, Fisher DE. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002, 109:707-18.
146. Goding CR. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev 2000, 14:1712-1728.
147. Thomson JA, Murphy K, Baker E, Sutherland GR, Parsons PG, Sturm RA, Thomson F. The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Oncogene 1995, 11:691-700.
148. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 1998, 391:298-301.
149. Bertolotto C, Abbe P, Hemesath TJ, Bille K, Fisher DE, Ortonne JP, Ballotti R. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol 1998, 142:827-835. 2148160, 9700169.
150. Bertolotto C, Bille K, Ortonne JP, Ballotti R. Regulation of tyrosinase gene expression by cAMP in B16 melanoma cells involves two CATGTG motifs surrounding the TATA box: implication of the microphthalmiagene product. Cell Sci 1996, 134:747-755.
151. Polakis P. Wnt signaling and cancer. Genes Dev 2000, 14:1837-1851.
152. Dorsky RI, Moon RT, Raible DW. Control of neural crest cell fate by the Wnt signalling pathway. Nature 1998, 396:370-373.
153. Dorsky RI, Moon RT, Raible DW. Environmental signals and cell fate specification in premigratory neural crest. Bioessays 2000, 22:708-716.
154. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesisa look outside the nucleus. Science 2000, 287:1606-1609.
155. You L, He B, Xu Z, Uematsu K, Mazieres J, Fujii N, Mikami I, Reguart N, McIntosh JK, Kashani-Sabet M, McCormick F, Jablons DM. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 2004, 64:5385-5389.
156. Kashani-Sabet M, Range J, Torabian S, Nosrati M, Simko J, Jablons DM, Moore DH, Haqq C, Miller III, Sagebiel RW. A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci USA 2009, 106:6268-6272. 2662963, 19332774.
157. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 1997, 275:1790-1792.
158. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of β-catenin without exon 3 mutations in malignant melanoma. Am J Path 1999, 154:325-329. 1850000, 10027390.
159. Morgan T. The theory of the gene. Am Nat 1917, 51:513-544.
160. Robbins J, Blondel BJ, Gallahan D, Callahan R. Mouse mammary tumor gene int-3: a member of the Notch gene family transforms mammary epithelial cells. J Virol 1992, 66:2594-2599. 289064, 1312643.
161. Jhappan C, Gallahan D, Stahle C, Chu E, Smith GH, Merlino G, Callahan R. Expression of an activated Notch-related int-3 trangene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev 1992, 6:345-355.
162. Lardelli M, Williams R, Lendahl U. Notch-related genes in animal development. Int J Dev Biol 1995, 39:769-780.
163. Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, Ray WJ, Kopan R. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell 2000, 5:197-206.
164. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Israël A. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 2000, 5:207-216.
165. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch. Nature 1995, 377:355-358.
166. Lai EC. Protein degradation: four E3s for the notch pathway. Curr Biol 2002, 12:R74-R78.
167. Lai EC. Notch signaling: control of cell communication and cell fate. Development 2004, 131:965-973.
168. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999, 284:770-776.
169. Jeffries S, Capobianco AJ. Neoplastic transformation by Notch requires nuclear localization. Mol Cell Biol 2000, 20:3928-3941. 85741, 10805736.
170. Allman D, Punt JA, Izon DJ, Aster JC, Pear WS. An invitation to T and more: notch signaling in lymphopoiesis. Cell 2002, 109:S1-S11.
171. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66:649-61.
172. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, Ball DW. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001, 61:3200-5.
173. Gestblom C, Grynfeld A, Ora I, Ortoft E, Larsson C, Axelson H, Sandstedt B, Cserjesi P, Olson EN, Påhlman S. The basic helix-loop-helix transcription factor dHAND, a marker gene for the developing human sympathetic nervous system, is expressed in both high- and low-stage neuroblastomas. Lab Invest 1999, 79:67-79.
174. Grynfeld A, Påhlman S, Axelson H. Induced neuroblastoma cell differentiation, associated with transient HES-1 activity and reduced HASH-1 expression, is inhibited by Notch1. Int J Cancer 2000, 88:401-10.
175. Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML, Artavanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci USA 1995, 92:6414-8. 41528, 7604005.
176. Talora C, Sgroi DC, Crum CP, Dotto GP. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 2002, 16:2252-63. 186663, 12208848.
177. Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao WQ. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res 2001, 61:7291-7.
178. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, Hui CC, Clevers H, Dotto GP, Radtke F. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003, 33:416-21.
179. Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, Aster JC, Krishna S, Metzger D, Chambon P, Miele L, Aguet M, Radtke F, Dotto GP. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 2001, 20:3427-36. 125257, 11432830.
180. Lowell S, Jones P, Le Roux I, Dunne J, Watt FM. Stimulation of human epidermal differentiation by δ-notch signalling at the boundaries of stem-cell clusters. Curr Biol 2000, 10:491-500.
181. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, Wu T, Niinobe M, Yoshikawa K, Hannigan GE, Halaban R. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004, 64:5270-82.
182. Massi D, Tarantini F, Franchi A, Paglierani M, Di Serio C, Pellerito S, Leoncini G, Cirino G, Geppetti P, Santucci M. Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Modern Pathology 2006, 19:246-259.
183. Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B, Zabierowski SE, Yashiro-Ohtani Y, Nathanson KL, Bengston A, Pollock PM, Weeraratna AT, Nickoloff BJ, Pear WS, Capobianco AJ, Herlyn M. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res 2009, 69:5312-5320.
184. Kang DE, Soriano S, Xia X, Eberhart CG, De Strooper B, Zheng H, Koo EH. Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell 2002, 110:751-762.
185. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration f melanoma cells. Cancer Res 2001, 61:3819-3825.
186. Cheng P, Zlobin A, Volgina V, Gottipati S, Osborne B, Simel EJ, Miele L, Gabrilovich DI. Notch-1 regulates NF-kB activity in hemopoietic progenitor cells. J Immunol 2001, 167:4458-4467.
187. Shin HM, Minter LM, Cho OH, Gottipati S, Fauq AH, Golde TE, Sonenshein GE, Osborne BA. Notch1 augments Nf-kB activity by facilitating its nuclear retention. EMBO J 2006, 25:129-138. 1356346, 16319921.
188. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, Rudolf M, Siziopikou K, Kast WM, Miele L. Activation of Notch1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Na Med 2002, 8:979-986.
189. Kiaris H, Politi K, Grimm LM, Szabolcs M, Fisher P, Efstratiadis A, Artavanis-Tsakonas S. Modulation of Notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. Am J Pathol 2004, 165:695-705. 1618582, 15277242.
190. Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S. Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide 2008, 19:133-137. 2577016, 18472017.
191. Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, Shapiro D, Le J, Koh SI, Kimura T, Green SJ, Mak TW, Taniguchi T, Vilcek J. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 1994, 263:1612-1615.
192. Martin E, Nathan C, Xie QW. Role of interferon regulatory factor 1 in induction of nitric oxide synthase. J Exp Med 1994, 180:977-984. 2191666, 7520478.
193. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 1994, 269:4705-4708.
194. Adcock IM, Brown CR, Kwon O, Barnes PJ. Oxidative stress induces NF kappa B DNA binding and inducible NOS mRNA in human epithelial cells. Biochem Biophys Res Commun 1994, 199:1518-1524.
195. Meyskens FL, McNulty SE, Buckmeier JA, Tohidian NB, Spillane TJ, Kahlon RS, Gonzalez RI. Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic Biol Med 2001, 31:799-808.
196. Zhang J, Peng B, Chen X. Expression of nuclear factor kappaB, inducible nitric oxide syntheses, and vascular endothelial growth tactor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res 2005, 11:7334-7343.
197. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Rev Immunol 1997, 15:323-350.
198. Bredt DS. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res 1999, 31:577-596.
199. Geller DA, Billiar TR. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev 1998, 17:7-23.
200. Massi D, Franchi A, Sardi I, Magnelli L, Paglierani M, Borgognoni L, Maria Reali U, Santucci M. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. J Pathol 2001, 194:194-200.
201. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, Fidler IJ. Transfection with the inducible nitric oxide syntheses gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995, 181:1333-1343. 2191958, 7535333.
202. Xie K, Wang Y, Huang S, Xu L, Bielenberg D, Salas T, McConkey DJ, Jiang W, Fidler IJ. Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2. Oncogene 1997, 15(7):771-9.
203. Messmer UK, Ankarcrona M, Nicotera P, Brüne B. p53 expression in nitric oxide induced apoptosis. FEBS Lett 1994, 355:23-26.
204. Rudin CM, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 1997, 48:267-281.
205. Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993, 74:777-779.
206. Krammer PH. The CD95(APO-1/Fas)/CD95L system. Toxicol Lett 1998, 102-103:131-137.
207. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999, 17:2941-2953.
208. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001, 13:555-562.
209. Brune B, Mohr S, Messmer UK. Protein thiol modification and apoptotic cell death as cGMP-independent nitric oxide (NO) signaling pathways. Rev Physiol Biochem Pharmacol 1996, 127:1-30.
210. Tschugguel W, Pustelnik T, Lass H, Mildner M, Weninger W, Schneeberger C, Jansen B, Tschachler E, Waldhör T, Huber JC, Pehamberger H. Inducible nitric oxide synthase (iNOS) expression may predict distant metastasis in human melanoma. Br J Cancer 1999, 79:1609-1612. 2362722, 10188914.
211. Ahmed B, Oord JJ. Expression of the inducible isoform of nitric oxide synthase in pigment cell lesions of the skin. Br J Dermatol 2000, 142:432-40.
212. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000, 6:4768-75.
213. Ahmed B, Oord JJ. Expression of the neuronal isoform of nitric oxide synthase (nNOS) and its inhibitor, protein inhibitor of nNOS, in pigment cell lesions of the skin. Br J Dermatol 1999, 141:12-19.
214. Tang CH, Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 2004, 279:288-98.
215. Bevona C, Goggins W, Quinn T. Cutaneous melanomas associated with nevi. Arch Dermatol 2003, 139:1620-1624.
216. Rasheed S, Mao Z, Chan JMC, Chan LS. Is melanoma a stem cell tumor? Identification of neurogenic proteins in trans-differentiated cells. J Transl Med 2005, 3:14. 1083422, 15784142.
217. Zabierowski SE, Herlyn M. Melanoma stem cells: the dark seed of melanoma. J Clin Oncol 2008, 26:2890-2894.